TRAIL and cancer immunotherapy: Take a walk on the short side.
TRAIL and cancer immunotherapy: Take a walk on the short side.
Clin Cancer Res. 2020 Aug 26;:
Authors: De Miguel D, Pardo J
Abstract
Recent work shows that TRAILshort, a membrane-bound short form of TRAIL, is expressed by human cancer cells and protects them from TRAIL-induced cell death. A monoclonal antibody that selectively targets TRAILshort enhances cancer susceptibility to TRAIL and increases the efficacy of autologous CD8+T cells in ex vivo primary tumours.
PMID: 32847932 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: De Miguel D, Pardo J Tags: Clin Cancer Res Source Type: research